Supriya Lifescience Limited has informed the Exchange regarding 'Email Communication To Shareholders Regarding Dividend Taxation Provisions'.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has written to shareholders explaining the tax deduction at source (TDS) rules that will apply to the final dividend recently declared by the company. The Board of Directors, at their May 27, 2025 meeting, recommended a final dividend of Re. 1.00 per share (50%) on equity shares of Rs. 2 face value for FY 2024-25, pending shareholder approval at the upcoming AGM. For resident shareholders, TDS will be deducted at 10% under Section 194, with no TDS for individuals whose total dividend from the company in FY 2025-26 does not exceed Rs. 10,000. Non-resident shareholders, FIIs and FPIs will face TDS at 20% (plus surcharge and cess), with the option to claim beneficial DTAA rates by submitting the required documents. Shareholders must submit the relevant declarations and documents to the company's RTA, MUFG Intime India, on or before July 14, 2025, after which no revisions will be entertained.
This is a routine procedural communication to help shareholders understand the TDS mechanics on the upcoming dividend. It has no direct impact on the stock price, but shareholders, especially non-residents, need to act before the July 14, 2025 deadline to avoid higher tax deductions on their dividend payouts.